Placebo + 0.5 mgTestosterone + 10 mg Buspirone
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoactive Sexual Desire Disorder
Conditions
Hypoactive Sexual Desire Disorder
Trial Timeline
Jul 1, 2013 → Oct 1, 2014
NCT ID
NCT02101203About Placebo + 0.5 mgTestosterone + 10 mg Buspirone
Placebo + 0.5 mgTestosterone + 10 mg Buspirone is a phase 2 stage product being developed by Brain Biotech for Hypoactive Sexual Desire Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT02101203. Target conditions include Hypoactive Sexual Desire Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02101203 | Phase 2 | Completed |
Competing Products
4 competing products in Hypoactive Sexual Desire Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + Testosterone + Buspirone hydrochloride | Brain Biotech | Phase 2 | 44 |
| Placebo + Sildenafil + Testosterone | Brain Biotech | Phase 2 | 44 |
| Bremelanotide + Placebo | Palatin Technologies | Phase 3 | 69 |
| Bremelanotide | Palatin Technologies | Phase 3 | 69 |